This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.







Fig. 14









Fig. 10












Fig. 2C HMEC = Nonmalignant primary mammary epithelial cells Solid line = antibody pool after selection on breast cancer cells or individual Fab clone A549 = lung carcinoma cell line 2087 = breast cancer cell line HL60 = leukemia cell line SKBR3 = breast cancer cell line MCF-7 = breast cancer cell line 3133 = breast cancer cell line 3199 = breast cancer cell line





Solid line = antibody pool after selection on breast cancer cells or individual Fab clone 2087 = breast cancer cell line **Key**: Dotted line = preselection antibodies SKBR3 = breast cancer cell line MCF-7 = breast cancer cell line


AD07 = preast cancer centrine


HMEC = Nonmalignant primary mammary epithelial cells


A549 = lung carcinoma cell line

HL60 = leukemia cell line

3133 = breast cancer cell line 3199 = breast cancer cell line







HMEC = Nonmalignant primary mammary epithelial cells Solid line = antibody pool after selection on breast cancer cells or individual Fab clone 2087 = breast cancer cell line SKBR3 = breast cancer cell line MCF-7 = breast cancer cell line

A549 = lung carcinoma cell line HL60 = leukemia cell line 3133 = breast cancer cell line 3199 = breast cancer cell line







Fig. 3



F1g. 4








Fig. 7A

| sample | | n CD19+ | /lgG+ | gG/lgD+ | CD19+/IgM+ | IgM+/IgD+ | n CD19+/lgG+ lgG/lgD+ CD19+/lgM+ lgM+/lgD+ CD19+/CD38+ CD19/CD40 CD19/CD95 | CD19/CD40 | CD19/CD95 |
|-------------|-------------------------------------|---------|-------|---------|------------|-----------|--|-----------|-----------|
| 1 L | | 9 | 92 | 40 | | | | | 11 |
| tumor-drair | umor-draining lymph node | 2 | 53 | 20 | | | | | 14 |
| PBMC- bre | PBMC- breast cancer pt | 2 | 41 | 8 | 47 | 06 | 46 | 65 | 45 |
| PBMC - he | PBMC - healthy donor | 4 | 23 | _ | | | | | 22 |
| | TILB | | | | | | | | |
| marker | specificity | | | | | | | | |
| | | | | | | | | | |
| BCL2 | antiapoptotic | hi | | | | | | | |
| CD10 | pre-B | 0 | | | | | | | |
| CD20 | 8 | Ë | | | | | | | |
| CD23 | activation | 0 | | | | | | | |
| CD27 | memory | 0 | | | | <i>:</i> | | | |
| CD38 | plasma cell | 0 | | | | | | | |
| CDS | T, autoimmune B | 0 | | | | Fig. 7 | മ | | |
| HLADR | B / APC | hi | | | |) | 1 | | |
| Ki-67/CD20 | Ki-67/CD20 B cell, proliferation lo | O] | | | | | | | |




Fig. 8